United Therapeutics (UTHR) Received its Third Buy in a Row

After J.P. Morgan and Ladenburg Thalmann & Co. gave United Therapeutics (NASDAQ: UTHR) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein reiterated a Buy rating on United Therapeutics yesterday and set a price target of $255.00. The company’s shares closed last Thursday at $221.35.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -11.2% and a 37.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for United Therapeutics with a $253.00 average price target, which is a 12.0% upside from current levels. In a report issued on August 3, Credit Suisse also maintained a Buy rating on the stock with a $254.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on United Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $462 million and net profit of $240 million. In comparison, last year the company earned revenue of $379 million and had a net profit of $28.3 million.

Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Read More on UTHR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More